Patient-reported reasons for discontinuing overactive bladder medication

BJU International

Volumn 105, Issue 9, 2010, Pages 1276-1282

  Benner, Joshua S ^a,b   Nichol, Michael B ^c   Rovner, Eric S ^d   Jumadilova, Zhanna ^e   Alvir, Jose ^e   Hussein, Mohamed ^a   Fanning, Kristina ^f   Trocio, Jeffrey N ^e   Brubaker, Linda ^g  

^a IQVIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e PFIZER INC   (United States)

^f VEDANTA RESEARCH   (United States)

^g LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Antimuscarinic agents; Latent class analysis; Overactive bladder; Survey

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; TOLTERODINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEALTH BELIEF; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERACTIVE BLADDER; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; SELF REPORT; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; UNITED STATES; URINARY BLADDER, OVERACTIVE; YOUNG ADULT;

EID: 77950801791     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.09036.x     Document Type: Article

References (18)

1. Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P. Reviewing the ICS 2002 Terminology Report. The ongoing debate. Neurourol Urodyn 2006 25 : 293
2. Andersson KE. Antimuscarinics for the treatment of overactive bladder. Lancet Neurol 2004 3 : 46 53
3. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008 54 : 543 562
4. Krueger KP, Berger BA, Felkey B. Medication adherence and persistence: a comprehensive review. Adv Ther 2005 22 : 313 356 (Pubitemid 43003324)
5. Noe L, Sneeringer R, Patel B, Williamson T. The implications of poor medication persistence with treatment for overactive bladder. Manag Care Interface 2004 17 : 54 60 (Pubitemid 40444166)
6. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005 353 : 487 497 (Pubitemid 41127293)
7. Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health 2005 8 : 495 505 (Pubitemid 41726103)
8. Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z. Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 2005 11 : S121 9 (Pubitemid 41022720)
9. D'Souza AO, Smith MJ, Miller LA, Doyle J, Ariely R. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm 2008 14 : 291 301 (Pubitemid 351711980)
10. Varadharajan S, Jumadilova Z, Girase P, Ollendorf DA. Economic impact of extended-release tolterodine versus immediate- and extended- release oxybutynin among commercially insured persons with overactive bladder. Am J Manag Care 2005 11 (Suppl. S140 9 (Pubitemid 41022722)
11. Basra RK, Wagg A, Chapple C et al. A review of adherence to drug therapy in patients with overactive bladder. BJU Int 2008 102 : 774 779
12. Coyne KS, Zyczynski T, Margolis MK, Elinoff V, Roberts RG. Validation of an overactive bladder awareness tool for use in primary care settings. Adv Ther 2005 22 : 381 394 (Pubitemid 43003328)
13. Magidson J, Vermunt JK. Latent class factor and cluster models, bi-plots, and related graphical displays. Sociol Methodol 2001 31 : 223 264 (Pubitemid 33584800)
14. Lo Y, Mendell NR, Rubin DB. Testing the number of components in a normal mixture. Biometrika 2001 88 : 767 778 (Pubitemid 33771022)
15. Balkrishnan R, Bhosle MJ, Camacho FT, Anderson RT. Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: a longitudinal cohort study. J Urol 2006 175 : 1067 1071 (Pubitemid 43200091)
16. Klutke CG, Burgio KL, Wyman JF et al. Combined effects of behavioral intervention and tolterodine in subjects dissatisfied with their overactive bladder medication. J Urol 2009 181 : 2599 2607
17. Wyman JF, Burgio KL, Newman DK. Practical aspects of lifestyle modifications and behavioral interventions in the treatment of overactive bladder and urgency urinary incontinence. Int J Clin Pract 2009 63 : 1177 1191
18. Bago d'Uva T. Latent class models for use of primary care: evidence from a British panel. Health Econ 2005 14 : 873 892